Rosadyn Six-Month Clinical Study Completed in Open Label Study Design
55 Test Subjects with moderate-to-severe rosacea who were classified as reatment-resistant cases were studied for six full months on Rosadyn. No other treatments were permitted during Rosadyn testing. We measured 19 Key rosacea variables at the end of Month One, Three and Six and are putting the final data into graphs and bar charts with statistical analysis (ANOVA statistical testing with post Hoc analysis for significance) and are including all the raw data showing the distribution of responses for each test subject.


Dozens of New Rosadyn Treatment Photos
We are adding dozens of new treatment clearance photos and preparing to publish the study in a peer-reviewed medical journal (Journal of Investigative Dermatology) along with two amazing case studies (Journal of the American Academy of Dermatology) that you can view on Rosadyn's home page. The two case studies are presented as Video series by Mark Wilson and Jason Cornelius on Rosadyn's Home Page for right now -- two long-time, severe rosacea sufferers treated by Dr. Bitter MD. for years and classified as treatment-resistant to topical rosacea treatments and oral rosacea treatments (e.g tetracycline, ORACEA, accutane, high dose clarithromycin, azithromycin, clonidine, beta-blockers, dozens of aggressive laser treatments, Clenia, Rosanil, Aczone, Metrogel, Metrocream, Metrolotion, Noritate and ZenMed)... now, after six months on rosadyn, they are both in full remission with very few triggers that have been downgraded from severe / debilitating to mild.


Flash Animated Power Point Presentation
We will present the clinical graphs as Flash-animated powerpoint slide shows and include dozens of new before and afer photos that are cropped out and enlarged by 500% with medical evaluation software so everyone can see detailed clearance of blood vessels, inflammatory cells, redness, flushing, telangiectasia, thin skin, rosacea dermatitis, swelling, papaules, pustules, superficial inflammed nerves, etc..


First Oral Rosacea Treatment to Address All Five Rosacea Subtypes
We are very excited by the outcome of this thorough clinical study as this is the first oral nutraceutical to treat all five subtypes of rosacea and suppress many rosacea triggers... and clearly out performs rosacea's only FDA-approved oral drug, ORACEA, on every level including the blockade of iflammatory Matrix Metalloproteinases (MMP-1, MMP-3 and MMP-9).


Upgrading Rosadyn to "Rosadyn Clinical"
In our strive to continually increase the efficacy of any rosacea product we put to market, we are researching the addition of three new medicinal Aryuvedic extracts to be put together as a "Rosadyn Clinical Kit".


Conclusion
Please visit our Rosadyn Website over the next two weeks to see these exciting new updates on the Rosadyn Home Page and an entire secondary page labelled, "Rosadyn Research Study Results".
Vascular Health Specialists, Dr. Patrick Bitter Sr. MD and myself would like to thank all the Rosacea Test Subjects for their time, detail, commitment to the study and professionalism.

Best.

__

__________________
_

Best,
Geoffrey

Dr. Geoffrey Nase
Ph.D: Neuro-Vascular Physiologist

Email: drnase1000@hotmail.com
Bibliography: http://drnase.com

All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer.